Amneal Seeks Federal Circuit Support to Affirm Delisting of Teva’s Inhaler Patents from Orange Book

Amneal Pharmaceuticals Inc. is urging the Federal Circuit to preserve a lower court decision that removed inhaler device patents from the Orange Book, an important government database. This delisting was secured following an infringement lawsuit initiated by Teva Pharmaceuticals USA Inc. Amneal argues that the decision properly differentiates between device patents and drug patents, effectively ensuring that only relevant drug patents are listed in the Orange Book. Read the detailed account of the ongoing legal process and its implications on Law360.